Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma

European Urology

Volumn 66, Issue 3, 2014, Pages 502-509

  McKay, Rana R ^a   Lin, Xun ^b   Perkins, Julia J ^b   Heng, Daniel Y C ^c   Simantov, Ronit ^b   Choueiri, Toni K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Pfizer Ltd   (United States)

^c TOM BAKER CANCER CENTRE   (Canada)

Author keywords

Bisphosphonates; Bone metastases; mTOR inhibitors; Renal cell carcinoma; VEGF targeted therapy

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AXITINIB; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CARBANILAMIDE DERIVATIVE; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; INDOLE DERIVATIVE; MTOR PROTEIN, HUMAN; NICOTINAMIDE; PAMIDRONIC ACID; PYRROLE DERIVATIVE; RAPAMYCIN; SORAFENIB; SUNITINIB; TARGET OF RAPAMYCIN KINASE; TEMSIROLIMUS; VASCULOTROPIN A; ZOLEDRONIC ACID;

AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE NEOPLASMS; CARCINOMA, RENAL CELL; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HYPOCALCEMIA; KIDNEY FAILURE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE;

AGED; ANTINEOPLASTIC AGENTS; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPOCALCEMIA; IMIDAZOLES; INDAZOLES; INDOLES; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; PYRROLES; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84905919157     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.02.040     Document Type: Article

References (27)

1. M. Bianchi, M. Sun, and C. Jeldres et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis Ann Oncol 23 2012 973 980
2. G.D. Roodman Mechanisms of bone metastasis N Engl J Med 350 2004 1655 1664
3. L.S. Rosen, D. Gordon, and S. Tchekmedyian et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group J Clin Oncol 21 2003 3150 3157
4. D.L. Lacey, W.J. Boyle, and W.S. Simonet et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab Nat Rev Drug Discov 11 2012 401 419
5. B. Beuselinck, S. Oudard, and O. Rixe et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib Ann Oncol 22 2011 794 800
6. R.R. McKay, N. Kroeger, and W. Xie et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy Eur Urol 65 2014 577 584
7. R.J. Motzer, M. Mazumdar, J. Bacik, W. Berg, A. Amsterdam, and J. Ferrara Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 1999 2530 2540
8. A. Lipton, M. Zheng, and J. Seaman Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma Cancer 98 2003 962 969
9. S. Maita, T. Yuasa, and N. Tsuchiya et al. Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function Int J Cancer 130 2012 677 684
10. N. Sathiakumar, E. Delzell, and M.A. Morrisey et al. Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999-2006 Breast Cancer Res Treat 131 2012 231 238
11. N. Sathiakumar, E. Delzell, and M.A. Morrisey et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006 Prostate Cancer Prostatic Dis 14 2011 177 183
12. H.J. Henk, and S. Kaura Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers J Med Econ 15 2012 185 194
13. K. Fizazi, M. Carducci, and M. Smith et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 2011 813 822
14. D.H. Henry, L. Costa, and F. Goldwasser et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma J Clin Oncol 29 2011 1125 1132
15. A.T. Stopeck, A. Lipton, and J.J. Body et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study J Clin Oncol 28 2010 5132 5139
16. C.A. Migliorati, S.B. Woo, and I. Hewson et al. A systematic review of bisphosphonate osteonecrosis (BON) in cancer Support Care Cancer 18 2010 1099 1106
17. F. Saad, J.E. Brown, and C. Van Poznak et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases Ann Oncol 23 2012 1341 1347
18. T. Smidt-Hansen, T.B. Folkmar, K. Fode, M. Agerbaek, and F. Donskov Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma J Oral Maxillofac Surg 71 2013 1532 1540
19. T.K. Choueiri, J.A. Garcia, and P. Elson et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy Cancer 110 2007 543 550
20. R.J. Motzer, B. Escudier, and S. Oudard et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
21. S. Patil, R.A. Figlin, and T.E. Hutson et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma Ann Oncol 22 2011 295 300
22. R.P. Riechelmann, S. Chin, and L. Wang et al. Sorafenib for metastatic renal cancer: the Princess Margaret experience Am J Clin Oncol 31 2008 182 187
23. Vrdoljak E, Szczylik C, Mardiak J, et al. Use of bisphosphonates in combination with sunitinib in renal cell cancer patients with bone metastases from the expanded access study. Abstract 2756 presented at: European Cancer Congress; September 30, 2013; Amsterdam, The Netherlands.
24. D. Keizman, M. Ish-Shalom, and R. Pili et al. Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma Eur J Cancer 48 2012 1031 1037
25. B. Beuselinck, P. Wolter, and A. Karadimou et al. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases Br J Cancer 107 2012 1665 1671
26. T. Yuasa, S. Urakami, and S. Yamamoto et al. Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis Clin Exp Metastasis 28 2011 405 411
27. R.J. Broom, V. Hinder, and K. Sharples et al. RAD001 and zoledronic acid in patients with renal cell carcinoma with bone metastases (RAZOR): a randomized phase II trial ASCO Meeting Abstracts 31 Suppl 6 2013 402